Largest biotech companies by total debt
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Amgen leads the 11 biotech companies ranked by total debt, at AED 200.5B, ahead of Gilead Sciences (AED 91.6B) and Biogen (AED 23.1B). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 11
- First
- AmgenAED 200.5B
- Median
- AED 2.2B
- Combined market value
- AED 3.09T
- Countries
- 5
- Not ranked
- 13no total debt on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total debt ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | AED 200.5B | AED 886.8B | AED 1,639.50 | 2.52% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | AED 91.6B | AED 769.9B | AED 620.74 | 0.73% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | AED 23.1B | AED 136.9B | AED 925.95 | 0.53% up | 49% up | ||
| 4 | Halozyme TherapeuticsHALO · Health Care | AED 7.9B | AED 40.3B | AED 353.87 | 0.40% up | 37% up | ||
| 5 | QiagenQGEN · Health Care | AED 6.1B | AED 37.7B | AED 182.54 | 0.10% down | 12% up | ||
| 6 | ModernaMRNA · Health Care | AED 2.2B | AED 296.8B | AED 733.59 | 3.42% down | 755% up | ||
| 7 | RepligenRGEN · Health Care | AED 2B | AED 40.7B | AED 636.86 | 6.92% up | 5% up | ||
| 8 | Bio-TechneTECH · Health Care | AED 734.6M | AED 42B | AED 267.40 | 0.24% up | 26% up | ||
| 9 | Adaptive BiotechnologiesADPT · Health Care | AED 481.9M | AED 17.1B | AED 105.76 | 1.07% up | 88% up | ||
| 10 | Scholar Rock HoldingSRRK · Health Care | AED 366.2M | AED 21.3B | AED 174.72 | 5.52% up | 14% up | ||
| 11 | CG OncologyCGON · Health Care | AED 11M | AED 26.3B | AED 294.67 | 1.63% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total debt is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Total debt is assembled from each company's debt lines and is the least complete of these figures: some companies tag part of their borrowings in ways it misses. Sums are converted from US dollars at today's exchange rate (1 USD = 3.6728 AED). 13 companies have no total debt on file and are not ranked here.
Questions and answers
Which biotech companies rank first by total debt?
Amgen (AED 200.5B), Gilead Sciences (AED 91.6B) and Biogen (AED 23.1B) are the top three of the 11 biotech companies ranked by total debt as of 18 Nov 2026, 18:41 UTC.
How many biotech companies are in this ranking?
11 are ranked by total debt. 13 more have no total debt on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 11 biotech companies ranked by total debt have a combined market value of AED 3.09T as of 18 Nov 2026, 18:41 UTC.
What does ranking by total debt measure?
Borrowings at the end of the latest fiscal year: long-term debt including the part due within a year, plus short-term borrowings. Leases are left out unless the company reports them in one figure with its debt.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total debt”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-debt
Underlying data: Yahoo Finance; SEC EDGAR.